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Background - Post-operative atrial fibrillation (POAF) occurs in 30-50% of patients undergoing 
cardiac surgery and is associated with increased morbidity and mortality. Prospective 
identification of structural/molecular changes in atrial myocardium that correlate with 
myocardial injury and precede and predict risk of POAF may identify new molecular pathways 
and targets for prevention of this common morbid complication.  
Methods - Right atrial appendage (RAA) samples were prospectively collected during cardiac 
surgery from 239 patients enrolled in the OPERA trial, fixed in 10% buffered formalin and 
embedded in paraffin for histology. We assessed general tissue morphology, cardiomyocyte 
diameters, myocytolysis (perinuclear myofibril loss), accumulation of perinuclear glycogen, 
interstitial fibrosis, and myocardial gap junction distribution. We also assayed NT-proBNP, hs-
cTnT, CRP, and circulating oxidative stress biomarkers (F2-isoprostanes, F3-isoprostanes, 
isofurans) in plasma collected before, during, and 48h after surgery. POAF was defined as 
occurrence of post-cardiac surgery atrial fibrillation or flutter of at least 30 seconds duration 
confirmed by rhythm strip or 12-lead ECG. The follow-up period for all arrhythmias was from 
surgery until hospital discharge or post-operative day 10. 
Results - 35.2% of patients experienced POAF. Compared to the non-POAF group, they were 
slightly older and more likely to have chronic obstructive pulmonary disease or heart failure.  
They also had a higher EuroSCORE and more often underwent valve surgery. No differences in 
left atrial size were observed between POAF and non-POAF patients. The extent of atrial 
interstitial fibrosis, cardiomyocyte myocytolysis, cardiomyocyte diameter, glycogen score or 
Cx43 distribution at the time of surgery was not significantly associated with incidence of 
POAF. None of these histopathologic abnormalities were correlated with levels of NT-proBNP, 
hs-cTnT, CRP or oxidative stress biomarkers.  
Conclusions - In sinus rhythm patients undergoing cardiac surgery, histopathological changes in 
the RAA do not predict POAF. They also do not correlate with biomarkers of cardiac function, 




Key words: pathology; atrial fibrillation; remodeling; biomarker; postoperative complication 




 http://ahajournals.org by on July 12, 2020
3 
Nonstandard Abbreviations and Acronyms 
AF: atrial fibrillation 
BNP: brain natriuretic peptide 
CRP: C-reactive protein 
Cx43: connexin 43 
ECG: electrocardiogram 
EuroSCORE: European system for cardiac operative risk evaluation 
n-3 PUFA: long-chain ω-3 polyunsaturated fatty acid 
NT-proBNP: N-terminal pro brain natriuretic peptide 
OPERA: omega-3 fatty acids for prevention of post-operative atrial fibrillation 
PAS: periodic acid–Schiff 
PCI: prior percutaneous coronary intervention 
POAF: post-operative atrial fibrillation 





Post-operative atrial fibrillation (POAF) is the most common complication of cardiac surgery 
ranging from 30% to 50% of cases and usually occurring within 2 to 4 days after the surgical 
procedure (with a peak incidence on post-operative day 2).1-4 POAF, in its turn, is associated 
with increased post-operative thromboembolic risk and stroke, hemodynamic compromise, 
ventricular dysrhythmias, as well as significantly higher both in-hospital and 6-month mortality.5 
In addition to the type of surgery, the only well-established predictor for the development of 
POAF is advanced age.6-11 
Remarkably, despite decades of recognition of POAF and attempts to mitigate its 
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hypothesis holds that both initiation and maintenance of this arrhythmia depend on a structural 
substrate that arises as a result of the multiple risk factors listed above3. However, a major 
limitation in developing preventive strategies has been a lack of understanding of the specific 
preceding anatomic and molecular changes in the atrial myocardium at the time of cardiac 
surgery that might influence the risk of POAF.  
Prior pathological studies have typically been retrospective (with tissue collected after 
onset of atrial fibrillation, AF), and have combined tissues from patients who had already 
experienced AF for variable intervals (e.g. new onset, paroxysmal, and persistent). These studies 
have also relied on what were likely non-representative samples obtained at convenience rather 
than pre-specified sampling by protocol. These limitations have made it impossible to identify 
and define rigorously the critical tissue substrates of AF, and to distinguish changes in tissue 
structure that increase the risk of AF from those caused by AF itself. 
Therefore, we set out to assess structural and molecular changes in atrial myocardium and 
circulating biomarkers collected prospectively in a large number of cardiac surgery patients to 
determine if any might be independently associated with the subsequent development of POAF.  
 
Methods 
The data that support the findings of this study are available from the corresponding author upon 
reasonable request. 
OPERA patient population and ω-3-PUFA supplementation 
The Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation (OPERA) study 
was a prospective, double-blind, placebo-controlled, multinational, randomized clinical trial that 
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supplementation reduces the occurrence of POAF after cardiac surgery.4, 12 The 1,516 patients 
enrolled in this trial were in sinus rhythm at the time of surgery. POAF was defined as “any 
documented AF or atrial flutter following cardiac surgery of at least 30 seconds duration and 
documented by rhythm strip or 12-lead electrocardiogram (ECG).  If only a shorter duration 
ECG is available, then the diagnosis of AF/atrial flutter is based on the arrhythmia being present 
at onset or termination”. The time period of follow-up for all arrhythmia endpoints was from the 
time of cardiac surgery until hospital discharge or post-op day 10, whichever occurred first.4 The 
protocol specified collection of blood samples before, during, and after surgery, and biopsy of 
the right atrial appendage (RAA) at the time of surgery. 
As a pre-specified substudy, RAA samples were prospectively collected during cardiac 
surgery from 292 OPERA patients. Out of these, 239 cases had RAA biopsies suitable for a 
reliable histopathological analysis and were the object of the present study. The baseline 
characteristics of this subsample was similar to the overall OPERA trial population 
(Supplementary Table 1).  All histological and biochemical analyses were performed centrally 
by skilled personnel unaware of patient characteristics, study treatment or outcomes. 
This study was approved by the IRB of all participating institutions and conducted 
according to international standards of Good Clinical Practice (FDA Title 21 part 312, 
International Conference on Harmonization guidelines). All patients provided written informed 
consent. 
Additional details are reported in the Data Supplement.  
Histopathologic and morphometric methods 
After excision, tissue specimens were fixed in 10% buffered formalin solution for at least 24 
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sections were cut for histopathological analyses aimed at exploring the most common changes 
observed in the setting of AF structural remodeling. RAA samples were initially observed in 
hematoxylin-eosin stained sections to evaluate general tissue morphology (Figures 1A-1B). To 
quantitate cardiomyocyte hypertrophy, the transverse diameters of 100 longitudinally oriented 
cardiomyocytes were measured (through the nucleus region) in PAS-stained sections using CellF 
software (Olympus Soft Imaging Solutions, version 2.6) (Figures 1C-1D)13. The presence of 
severe perinuclear myofibril loss in cardiomyocytes (so-called “myocytolysis”) was also 
determined in the same PAS-stained sections13. The percentage of cardiomyocytes showing 
myocytolysis was assessed at a magnification of x400. Accumulation of glycogen in the 
perinuclear area in cells showing myocytolysis is an indicator of a metabolic shift from the use of 
fatty acids to glucose. The presence of glycogen granules was evaluated at a magnification of 
x400 and scored semi-qualitatively into three categories: none (absent), mild-moderate, severe. 
Examples are shown in Figure 2. 
The percentage of myocardium occupied by interstitial fibrosis was assessed at a 
magnification of x400 in Van Gieson-stained sections (Figure 3). To quantify fibrosis, a light 
microscope equipped with an ocular reticule containing 42 sampling points was used. The 
fraction of points overlying interstitial fibrosis was accurately counted and multiplied by 100.14 
Connexin 43 distribution 
A primary antibody against the major myocardial gap junction protein connexin 43 (Cx43; 
SIGMA Aldrich, polyclonal, code C6219, dilution 1:400, overnight at 4°C) was used to 
characterize the distribution of gap junctions in cardiomyocytes.  
Detailed descriptions of the standard immunofluorescence methods have previously been 
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(H+L) (Jackson Immunoresearch, Cambridgeshire, UK; catalog number 111-165-144; dilution 
1:400) and the localization of Cx43 was qualitatively evaluated through a confocal microscope 
(Zeiss 510, Belgium) at an original magnification of x40. No attempt was made to quantify 
immunoreactive signals. Rather, we optimized the staining protocol to identify the lowest 
antibody concentration that shows a strong signal at intercalated disks in normal myocardial 
samples. We then assessed changes in the amount and/or distribution of signal in the tissue 
samples. As shown in Figure 4, Cx43 signal was categorized as a) control-like, when strong 
signal occurred in a normal junctional distribution; b) depressed, when the amount of signal was 
reduced; c)heterogeneous, if both a) and b) conditions coexisted; or d) absent. The extent to 
which Cx43 immunoreactive signal was redistributed to the lateral borders of cardiomyocytes 
was categorized as either minimal/absent or present. 
Statistical analyses 
Multivariate linear and logistic regression analyses were employed to assess the relation of 
circulating markers [brain batriuretic peptide (BNP), troponin, C-reactive protein (CRP), plasma 
and urine F2-isoprostanes, F3-isoprostanes, isofurans] with the atrial histopathological endpoints. 
Detailed description of the performed analyses is described in the Supplement Material.  
Supplementary Methods 
Methods regarding assay of circulating cardiac markers and oxidative stress biomarkers are 
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Results 
Characteristics of patients undergoing atrial biopsy 
RAA tissue samples were obtained from 239 patients, of whom 141 were American participants 
and 98 Italian patients. Characteristics of the overall population and those in the current 
histological sub-study were similar and are summarized in Supplementary Table 1. 
The mean age of study patients was 64.8±12.6 years; 72.4% were male, and 53/239 
patients (21.2%) had heart failure, 8% had experienced previous AF, 17.2% had prior 
percutaneous coronary interventions (PCI), and 4.3% had undergone previous cardiac surgery. 
The median logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation) 
value was 3.8 (interquartile range [IQR], 1.9-8.4). Valve surgery was performed in 58.8% of 
patients; see also Table 1. 
Eighty-four patients (35.2%) developed POAF. Compared to patients who did not 
develop POAF, these patients were older (67.2 vs. 63.5, p=0.03) and more likely to have chronic 
obstructive pulmonary disease (22.6% vs 12.3%, p=0.04). Further, they presented more often 
with heart failure (29.3% vs 18.2%, p=0.04), experienced more prior AF episodes (17.9% vs 
2.6%, p<0.001), and had a higher EuroSCORE (4.8 vs 3.1, p=0.04). They were also likely to 
have undergone valve surgery (69.1% vs 53.3%, p=0.02), compared to those in the non-POAF 
group. Left atrial size (41.5 vs 42.2, p=0.56) and left ventricular ejection fraction (58.4 vs 57.3, 
p=0.47) were comparable between the two groups (Table 1). 
Histopathological, morphometric and Connexin 43 analyses  
None of the histological variables (amount of interstitial fibrosis, cardiomyocyte myocytolysis, 
cardiomyocyte diameter, glycogen score, Cx43 distribution analysis) significantly differed 
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regression model adjusted for all statistically significant clinical variables and including all 
histological features, the following factors independently associated with incident POAF: age 
(OR: 1.05 95% CI: 1.01-1.09, p=0.021), history of prior AF (OR: 11.6, 95% CI: 2.26-59.0, 
p=0.003), and congestive heart failure (OR=0.37, 95%CI:0.16-0.85, P=0.018). None of the 
histological features (e.g. fibrosis, myocytolysis, cardiomyocyte diameter, glycogen 
accumulation, Cx43 patterns) reached statistical significance.  A non-significant trend was seen 
between presence of Cx43 lateralization at the time of cardiac surgery and lower future risk of 
POAF (OR=0.460, 95% CI=0.191-1.104, P=0.084). 
We also explored the univariate relationships between baseline characteristics of the 
population and the histological features of the right atrium at the time of cardiac surgery. Patients 
with angina pectoris had a higher fibrosis percentage (p=0.034; Supplementary Table 2); men 
had more myocytolysis than women (p=0.022); and patients with diabetes mellitus showed more 
perinuclear myofibril loss and moderate accumulation of glycogen (p=0.022, p=0.003 
respectively). Cx43 junctional signal (Figure 4) was depressed at intercalated disks in patients 
with COPD (p=0.006) and with higher EuroSCORE index (p=0.043). Interestingly, patients 
randomized to the n-3 PUFA treatment had less frequent lateralization of Cx43, compared with 
the placebo group (p=0.035) (data not shown).  These exploratory analyses were not corrected 
for multiple comparisons and should be interpreted with caution. 
Since the administration of n-3 PUFA correlated with reduced Cx43 lateralization, we 
determined if it also impacted POAF development in the subgroup in which Cx43 lateralization 
was present. However, compared with placebo, n-3 PUFA treatment did not significantly alter 
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Histopathological features and biomarker concentrations 
In multivariable-adjusted analyses, biomarker levels of cardiac strain, inflammation, and 
oxidative stress were generally not significantly associated with histopathological features of the 
right atrium at the time of cardiac surgery (Tables 3 and 4). The most notable association was an 
inverse association between N-terminal pro brain natriuretic peptide (NT-proBNP) levels and 
those of myocytolysis (p=0.001): mean NT-proBNP levels were about twice as high in the 
lowest tertile of myocytolysis, compared to the highest tertile. 
 
Discussion 
POAF and its currently-known predisposing factors 
POAF commonly complicates cardiac surgery, and represents a major contributor to post-
operative morbidity and increased length of stay and other healthcare utilization.1 Its incidence 
has increased significantly over the few past decades, likely because of the aging of the patient 
populations undergoing cardiac surgery. Despite substantial investigation, the pathologic and 
pathophysiologic variables that can reliably predict development of POAF and might provide 
mechanistic insight into its pathogenesis remain elusive.17 
POAF onset peaks on the second post-operative day, which suggests a key role for acute 
surgery-induced factors.17 Inflammation and oxidative stress related to atrial trauma during 
surgery, systemic inflammation, and stress related to cardiopulmonary bypass may all contribute 
to supraventricular arrhythmogenesis. Atrial enlargement due to intravenous fluid administration 
post-operatively may also predict POAF. All these early changes have the potential of creating 
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In addition to the above-mentioned factors directly related to surgery, various features 
reflecting chronic cardiac remodeling might increase POAF risk by creating anatomical 
substrates that promote arrhythmia maintenance. Aging itself correlates strongly with POAF 
presumably due, at least in part, to age-related collagen deposition within atrial myocardium 
which may favor fragmentation and reentrant arrhythmogenesis. Associated co-morbidities, such 
as systolic dysfunction, hypertension, COPD, and obesity, may also increase POAF risk.  
Major strengths of the present investigation 
The present investigation – an ancillary study to the large, placebo-controlled, double-blind 
randomized OPERA clinical trial – is the most comprehensive prospective evaluation to-date of 
how key structural and molecular characteristics of the right atrial myocardium at the time of 
surgery relate to the subsequent risk of POAF. Prior studies of myocardial histopathology and 
AF have nearly always been cross-sectional, i.e., with myocardial sampling occurring after AF is 
already present; and utilized convenience samples rather than a more general, prospectively 
ascertained population of patients undergoing cardiac surgery.  Major strengths of the present 
study include (a) analysis of the largest number of prospectively collected (prior to AF onset) 
atrial tissue samples; (b) analysis of a defined, well characterized multi-center patient population 
in sinus rhythm at the time of cardiac surgery (previously, it has been impossible to distinguish 
changes in tissue structure that increased risk of AF from those associated to persistent AF); and 
(c) the broad inclusion criteria of OPERA and its multi-center, multi-country design which 
maximized generalizability of our findings to the real-world population of patients, while 
minimizing potential bias from patient selection. Other strengths include participation by two 
experienced cardiac pathologists who were members of the OPERA Biological Studies 
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myocardium and anatomic substrates of cardiac arrhythmias, ensuring a coordinated and rigorous 
approach; and a generalizable patient population with overall characteristics and incidence of 
POAF resembling those reported in numerous previous large patient samples. 
POAF occurrence and the levels of circulating cardiac/oxidative stress biomarkers are not 
correlated with the structural remodeling of the RAA 
Despite the above-mentioned strengths, this investigation did not demonstrate any consistent 
statistically significant relationships between structural remodeling of the RAA (e.g., interstitial 
fibrosis, percentage of myocytolytic cardiomyocytes, muscle-cell hypertrophy, Cx43 
distribution) and development of POAF. Similarly, levels of circulating cardiac biomarkers (e.g., 
NT-proBNP, high-sensitivity cardiac troponin T, high sensitivity C-reactive protein)18 and 
oxidative stress biomarkers (e.g., F2-isoprostanes, F3-isoprostanes, isofurans)19 did not correlate 
with the presence of these histopathologic abnormalities. One exception is the counterintuitive 
highly significant relation (Table 3, p=0.003) between plasma F2-isoprostanes and fibrosis. This 
is, most likely, a chance finding attributable to the multiplicity of comparisons.  
To our knowledge, the present study represents the largest prospective investigation to-
date of these crucial relationships in cardiac surgery patients. Yet, while the sample size of 
nearly 250 patients is impressive for a prospective collection, it may have been insufficient to 
convincingly detect more subtle relationships between structural remodeling of the RAA, 
biomarkers of cardiac stress and inflammation, and risk of POAF.  The findings relating to Cx43 
lateralization, randomized n-3 PUFA treatment, and POAF; to NT-proBNP and myocytolysis; 
and to other associations that did not achieve statistical significance, provide an important 
foundation for further hypothesis generation and subsequent prospective studies to elucidate the 
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Review of the literature 
With these issues in mind, we reviewed 49 clinical and experimental studies focusing on the 
relationship between RAA structural remodeling and, broadly speaking, AF (either post-
operative or non-surgery associated; Table 5 and Table 6, respectively). This included 19 studies 
on POAF and 30 (5 in animal models) on non-POAF supraventricular arrhythmia. Studies on 
POAF assessed the predictive value of histological alterations for incident AF, while in the other 
30 studies associations between ongoing AF and histological alterations were assessed. Specific 
experimental designs differed, and relatively few studies comprehensively investigated multiple 
aspects of structural remodeling of the RAA including fibrosis, myocytolysis, cardiomyocyte 
hypertrophy, and connexins. The results varied considerably regarding specific histopathological 
features that correlated with AF. None of these previous studies were double-blind, placebo-
controlled, multinational, and randomized in nature as the present OPERA sub-study was and in 
which these biases were minimized. These methodological differences may be largely 
responsible for the higher frequency of significant relationships between histological features 
and risk of POAF seen in previous studies. Another concern involves use of automatic 
measurements, used in many prior studies, which may incorrectly classify and overestimate the 
extent of histological changes. In this regard, 19 previous studies (39%) used automatic 
morphometry methods, 8 (16%) used semi-automatic measurements, and 22 (49%) involved 
non-automatic (manual) histopathological evaluations. Only 13 of 19 investigations on POAF 
(68%) and 6 of 30 studies on non-POAF (20%) employed multivariate data analysis. Finally, the 
sample size of the various populations under investigation differed substantially between studies 
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Limitations of the study 
One potential limitation was the RAA sampling site, selected for both ethical and practical 
reasons in this large trial. While the RAA would be expected to undergo remodeling in response 
to AF, which involves the entire atrial myocardium, it may not exhibit the full range of 
pathogenic changes in a pre-AF stage as it may be more protected than the left atrium from the 
effects of many AF-associated conditions. Only a minority of OPERA patients had isolated right 
heart dysfunction. In addition, AF usually arises in the pulmonary veins and then progressively 
affects the left atrium, especially its posterior wall.20 Thus, the RAA may not be an ideal biopsy 
site to identify structural and molecular determinants of POAF in patients with mainly left-sided 
cardiac disease. 
Conclusions 
In conclusion, in this large, prospective clinico-pathological analysis of patients in sinus rhythm 
undergoing cardiac surgery, histopathological features of the RAA at the time of surgery did not 
significantly correlate with the subsequent development of POAF, and baseline biomarkers of 
cardiac inflammation and oxidative stress also generally did not associate with the RAA 
histopathological features.  These novel findings provide an important foundation for further 
hypotheses and prospective studies to elucidate the crucial unanswered questions on atrial 
structural remodeling and POAF risk. 
 
Sources of Funding: The OPERA trial was funded by the National Heart, Lung, and Blood 
Institute, National Institutes of Health (RC2-HL101816), GlaxoSmithKline, Sigma Tau, and 
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Table 1. Baseline characteristics prior to cardiac surgery in relation to Post-Operative Atrial 
Fibrillation. 
 
Variables Total Non-POAF POAF P* 
N (%) 239 155 (64.8%) 84 (35.2%)  
Age 64.8 ± 12.6 63.5 ± 13.3 67.2 ± 10.7 0.028 
Sex 
Female 66 (27.6%) 41 (26.5%) 25 (29.8%) 
0.585 Male 173 (72.4%) 114 (73.6%) 59 (70.2%) 
Treatment 
Placebo 122 (51.0%) 80 (51.6%) 42 (50.0%) 
0.812 n-3 PUFA 117 (49.0%) 75 (48.4%) 42 (50.0%) 
Current smoking 25 (10.6%) 17 (11.1%) 8 (9.6%) 
 
0.726 
COPD 38 (15.9%) 19 (12.3%) 19 (22.6%) 0.037 
Diabetes Mellitus 72 (30.1%) 45 (29.0%) 27 (32.1%) 0.617 
Hypertension 196 (82.0%) 123 (79.4%) 73 (86.9%) 0.147 
Chronic renal failure 11 (4.6%) 8 (5.2%) 3 (3.6%) 0.751 
Prior myocardial infarction 57/236 (24.2%) 38/154 (24.7%) 19/82 (23.2%) 0.797 
Angina pectoris 51/208 (24.5%) 30/134 (22.4%) 21/74 (28.4%) 0.336 
Heart Failure 53 (22.3%) 28 (18.2%) 25 (29.8%) 0.040 
Previous PCI 41 (17.2%) 25 (16.1%) 16 (19.1%) 0.568 
Previous AF 19 (8.0%) 4 (2.6%) 15 (17.9%) <0001 
Prior cardiac surgery† 10 (4.3%) 6 (3.9%) 4 (4.8%) 0.744 
Coronary bypass 5 (2.1%) 5 (3.2%) 0 1.000 
Valve surgery 3 (1.3%) 1 (0.7%) 2 (2.4%) 0.283 
Other cardiac surgery 3 (1.3%) 1 (0.7%) 2 (2.4%) 0.283 
LA size (mm) 41.8 ± 7.2 41.5 ± 7.1 42.2 ± 7.5 0.562 
LVEF(%) 58.0 ± 10.4 58.4 ± 11.0 57.3 ± 9.3 0.469 
B-Blockers 113 (53.6%) 70 (51.1%) 43 (58.1%) 0.330 
Statins 113 (53.6%) 71 (51.8%) 42 (56.8%) 0.493 
ACE or ARB 116 (55.0%) 74 (54.0%) 42 (56.8%) 0.702 
Diuretics 58 (27.5%) 40 (29.2%) 18 (24.3%) 0.449 
ASA 128 (60.7%) 81 (59.1%) 47 (63.5%) 0.533 
Antiarrhythmics 9 (4.3%) 3 (2.2%) 6 (8.1%) 0.069 
EuroSCORE 
Add-scale 5.1 ± 3.0 4.8 ± 3.1 5.7 ±2.7 0.041 
Log-scale 3.8 [1.9 – 8.4] 3.1 [1.6 – 7.9] 4.8 [2.3 – 8.6] 0.040 
Valve Surgery  
No 98/238 (41.2%) 72/154 (46.8%) 26/84 (30.9%) 
0.018 Yes 140/238 (58.8%) 82/154 (53.3%) 58/84 (69.1%) 
Pump time (hours) 1.64 ± 0.69 1.59 ± 0.71 1.74 ± .64 0.105 
Cross time (hours) 1.20 ± 0.54 1.16 ± 0.57 1.29 ± 0.48 0.072 
Cardioplegia 232 (97.5%) 148 (96.1%) 84 (100.0%) 0.093 
Blood transfusion 98 (41.2%) 63 (40.9%) 35 (41.7%) 0.910 
 
* P-value for Chi2 Test (discrete variables), ANOVA (normally distributed continuous variables) or Kruskal-Wallis 
(not normally distributed continuous variables) 
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Table 2. Histological characteristics at the time of cardiac surgery in relation to subsequent risk of Post-Operative Atrial Fibrillation. 
 
 
* P-value for Chi2 (discrete variables), ANOVA (normally distributed continuous variables) or Kruskal-Wallis (not normally distributed continuous variables). 
† P-value for multivariable Logistic regression adjusted for age, COPD, atrial fibrillation, congestive HF, valvular surgery and log EuroSCORE. 
Three classes of Connexin 43: normal pattern (patients with control Cx43 junctional and little/absent Cx43 lateralization); normal + abnormal pattern (patients 
with control Cx43 junctional and present Cx43 lateralization or patients with depressed Cx43 junctional and little/absent Cx43 lateralization); abnormal pattern 
(patients with depressed Cx43 junctional and present Cx43 lateralization; or patients with heterogeneous Cx43 junctional and present Cx43 lateralization).
 All Patients Non-POAF POAF P* univariate 
OR (95% CI) 
multivariable P† 
Fibrosis (%) 8.21 [5.02–12.65] 8.34 [5.28–12.65] 7.55 [4.51–12.50] 0.356 0.995 (0.959-1.032) 0.793 
Myocytolysis (%) 3.9 [1.7–8.4] 4.0 [1.8–8.8] 3.7 [1.3–6.9] 0.277 0.974 (0.914-1.039) 0.427 
Cardiomyocytes Diameter (µm) 14.8 ± 2.6 14.9 ± 2.6 14.7 ± 2.6 0.559 0.915 (0.810-1.034 0.155 
Glycogen accumulation 
None 58 (26.1%) 35 (23.3%) 23 (31.9%) 
0.346 
Reference 
Mild-Moderate 147 (66.2%) 104 (69.3%) 43 (59.7%) 0.628 (0.312-1.263) 0.192 
Severe 17 (7.7%) 11 (7.3%) 6 (8.3%) 0.865 (0.256-2.921) 0.815 
Cx43 Laterization 
Little/Absent 30 (12.9%) 17 (11.3%) 13 (16.1%) 
0.300 
Reference 
Present 202 (87.1%) 134 (88.7%) 68 (83.9%) 0.460 (0.191-1.104) 0.082 
Cx43 Junctional   
Control-like 139 (59.9%) 97 (64.2%) 42 (51.8%) 
0.141 
Reference 
Depressed 77 (33.2%) 46 (30.5%) 31 (38.3%) 1.503 (0.785-2.877) 0.219 
Heterogeneous 16 (6.9%) 8 (5.3%) 8 (9.9%) 2.174 (0.682-6.932) 0.189 
Connexin 43 
Normal + Normal 11 (4.8%) 9 (6.0%) 2 (2.5%) 
0.566 
Reference 
Normal + Abnormal 127 (64.8%) 87 (64.9%) 40 (64.5%) 1.139 (0.222-5.840) 0.876 
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Table 3. Pre-operative levels of biomarkers of cardiac strain, inflammation, and oxidative stress in relation to tertiles of continuous 
histopathological features of the right atrium at the time of cardiac surgery. 
 
Fibrosis (%) Tertile 1 N=79 (2.00-5.99) Median [IQR] 
Tertile 2 N=80  
(6.00-10.59) Median [IQR] 
Tertile 3 N=80  
(10.59-65.83) Median [IQR] P* 
Adjusted unit difference 





NT-proBNP 271 [120-853] 255 [95 - 615] 463 [188 - 888] 0.152 1.50 (-0.74-3.74) 0.187 
Hs cTnT 10.7 [5.9-18.5] 10.8 [6.3 – 21.1] 14.3 [9.0 - 23.8] 0.109 1.71 (-0.87–4.29) 0.193 
Hs-CRP 2.7 [1.0-5.2] 2.1 [1.0 - 5.9] 2.8 [1.1 - 6.9] 0.426 1.00 (-1.16–3.17) 0.363 
F2-isoprostanes 41 [31-52] 40 [31 - 56] 41 [31 - 51] 0.962 -7.71 (-12.84-2.59) 0.003 
F3-isoprostanes 1.6 [0.5-3.3] 1.0 [0.5 – 3.0] 1.5 [0.5 – 4.0] 0.852 1.94 (-0.73–4.60) 0.154 
Isofurans 37 [28-51] 35 [25 - 50] 36 [20 - 53] 0.578 -0.99 (-4.49–2.52) 0.580 
ur
in
e F2-isoprostanes 1.16 [0.77-2.03] 1.19 [0.95 - 1.96] 1.15 [0.81 - 1.47] 0.297 -1.81 (-6.71–3.10) 0.468 
F3-isoprostanes 0.11 [0.05-0.19] 0.12 [0.07 - 0.23] 0.13 [0.07 - 0.19] 0.748 1.69 (-0.82–4.19) 0.185 
Isofurans 1.79 [1.19-2.60] 1.74 [1.28 - 2.43] 1.80 [1.08 - 2.29] 0.774 -1.11 (-5.65–3.43) 0.629 
Myocytolysis (%) Tertile 1 N=74 (0.00 – 2.22) Median [IQR] 
Tertile 2 N=74 
(2.23 – 6.05) Median [IQR] 
Tertile 3 N=74 
(6.05 – 26.85) Median [IQR] P* 
Adjusted unit difference 





NT-proBNP 403 [175-1036] 292 [140 - 951] 203 [69 - 542] 0.012 -2.24 (-3.59—0.90) 0.001 
Hs cTnT 11.3 [6.9-16.6] 10.0 [5.9 - 20.9] 12.5 [7.7 - 21.6] 0.529 -0.08 (-1.67 – 1.51) 0.919 
Hs-CRP 2.1 [1.0-5.7] 2.9 [0.9 – 7.0] 2.1 [1.0- 5.7] 0.868 0.07 (-1.27 – 1.41) 0.922 
F2-isoprostanes 44 [33-55] 39 [30 - 50] 38 [29 - 52] 0.181 -0.68 (-4.36 – 2.99) 0.714 
F3-isoprostanes 1.0 [0.5–4.0] 2.0 [0.5 – 4.0] 1.0 [0.5 - 3.2] 0.144 -0.45 (-2.16 – 1.25) 0.602 
Isofurans 35 [25-54] 38 [23 - 53] 35 [27 - 49] 0.783 0.09 (-2.09 – 2.28) 0.934 
ur
in
e F2-isoprostanes 1.16 [0.83-1.57] 1.16 [0.80 - 1.79] 1.18 [0.82 - 1.88] 0.859 1.58 (-1.31 – 4.46) 0.281 
F3-isoprostanes 0.12 [0.07-0.22] 0.13 [0.06 - 0.21] 0.10 [0.05 - 0.19] 0.404 -1.25 (-2.68 – 0.19) 0.089 
Isofurans 1.74 [1.19-2.45] 1.88 [1.45 - 2.60] 1.74 [1.11 - 2.29] 0.672 -0.10 (-2.78 – 2.58) 0.942 
Cardiomyocyte 
diameter, µm 
Tertile 1 N=74 
(8.44 – 13.75) Median [IQR] 
Tertile 2 N=74 
(13.76 – 15.67) Median [IQR] 
Tertile 3 N=74 
(15.72 – 23.42) Median [IQR] P* 
Adjusted unit difference 





NT-proBNP 246 [124 - 861] 271 [120 - 888] 336 [158 - 713] 0.860 -0.36 (-1.08 – 0.36) 0.325 
Hs cTnT 10.1 [6.2 - 16.1] 9.3 [5.7 - 19.9] 15.6 [8.3 - 22.4] 0.016 0.78 (-0.04 – 1.60) 0.063 
Hs-CRP 1.3 [0.8 - 6.6] 2.1 [1.1 - 5.2] 3.1 [1.7 - 9.2] 0.030 0.68 (-0.02 – 1.37) 0.056 
F2-isoprostanes 42 [32 - 63] 40 [31 - 49] 40 [31 - 51] 0.337 -0.35 (-2.27 – 1.56) 0.715 
F3-isoprostanes 2.0 [0.5 – 4.0] 1.0 [0.5 – 3.0] 1.0 [0.5 - 3.3] 0.214 -0.26 (-1.14 – 0.63) 0.568 
Isofurans 36 [28 - 54] 33 [21 - 50] 37 [26 - 50] 0.428 -0.22 (-1.36 – 0.91) 0.697 
ur
in
e F2-isoprostanes 1.18 [0.84 - 1.59] 1.14 [0.75 - 1.75] 1.29 [0.94 - 1.92] 0.261 0.94 (-0.60 – 2.48) 0.230 
F3-isoprostanes 0.13 [0.06 - 0.24] 0.09 [0.05 - 0.15] 0.14 [0.09 - 0.22] 0.056 0.58 (-0.22 – 1.37) 0.153 
Isofurans 1.81 [1.20 - 2.56] 1.56 [1.16 - 2.17] 2.03 [1.46 - 2.61] 0.136 0.55 (-0.88 – 1.99) 0.446 
 
* P for Kruskall Wallis test. † All biomarkers were log-transformed and included in linear regression analysis with histopathological feature as dependent adjusted 
for age, COPD, history of atrial fibrillation, heart failure, valve surgery and EuroSCORE log. Beta represents the % unit difference in histopathologic features for 
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Table 4. Pre-operative levels of biomarkers of cardiac strain, inflammation, and oxidative stress in 
relation to categories of histopathological features of the right atrium at the time of cardiac surgery. 
 















NT-proBNP 308 [132 - 674] 266 [123 - 853] 625 [77 – 1132] 0.966 0.85 (0.47-1.54) 0.600 
Hs cTnT 9.3 [5.7 - 14.5] 14.0 [7.4 - 23.2] 9.0 [5.2 - 45.9] 0.023 2.46 (1.02-5.92) 0.045 
Hs-CRP 1.4 [0.9 - 5.4] 2.7 [1.1 - 6.7] 2.6 [1.6 - 6.6] 0.118 1.76 (0.96-3.22) 0.068 
F2-isoprostanes 44 [32 - 55] 39 [30 - 51] 42 [34 - 52] 0.565 0.36 (0.07-1.80) 0.214 
F3-isoprostanes 1.0 [0.5 – 4.0] 1.6 [0.5 - 3.6] 2.0 [0.5 – 4.0] 0.865 1.22 (0.59-2.55) 0.591 
Isofurans 34 [20 - 59] 36 [27 - 50] 45 [32 - 53] 0.371 1.57 (0.59-4.22) 0.371 
ur
in
e F2-isoprostanes 1.18 [0.88 - 1.59] 1.18 [0.81 - 1.66] 1.12 [0.88 - 2.02] 0.960 0.78 (0.22-2.76) 0.695 
F3-isoprostanes 0.13 [0.08 - 0.24] 0.11 [0.05 - 0.19] 0.07 [0.01 - 0.12] 0.054 0.29 (0.13-0.67) 0.004 
Isofurans 1.77 [1.36 - 2.25] 1.82 [1.17 - 2.53] 1.75 [1.48 - 2.47] 0.908 1.05 (0.32-3.44) 0.940 
Cx43 Laterization Little / absent N=30 
Present 
N=202 P* 






NT-proBNP 459 [237 - 760] 267 [125 - 847] 0.368 0.78 (0.21 -1.11) 0.087 
Hs cTnT 12.7 [5.9 - 15.7] 11.3 [6.9 - 21.8] 0.269 1.47 (0.51-4.21) 0.471 
Hs-CRP 3.1 [1.0 - 5.7] 2.3 [1.0 - 6.3] 0.977 1.05 (0.47-2.35) 0.904 
F2-isoprostanes 39 [33 - 53] 41 [31 - 52] 0.683 0.27 (0.04-1.78) 0.174 
F3-isoprostanes 3.0 [0.5 – 4.0] 1.2 [0.5 - 3.2] 0.191 0.67 (0.26-1.70) 0.400 
Isofurans 39 [28 - 59] 36 [25 - 50] 0.233 0.42 (0.13-1.36) 0.145 
ur
in
e F2-isoprostanes 1.21 [0.8 - 2.02] 1.18 [0.83 - 1.64] 0.751 1.13 (0.20-6.44) 0.888 
F3-isoprostanes 0.19 [0.1 - 0.34] 0.12 [0.06 - 0.19] 0.039 0.31 (0.08-1.16) 0.081 
Isofurans 1.61 [1.01 - 2.60] 1.78 [1.23 - 2.30] 0.330 2.68 (0.59-12.27) 0.205 














NT-proBNP 273 [108 - 759] 323 [158 - 875] 304 [180 – 1024] 0.406 1.41 (0.77-2.56) 0.262 
Hs cTnT 12.7 [7.0 - 22.4] 10.9 [7.1 - 20.3] 5.8 [5.0 - 16.5] 0.351 0.90 (0.46-1.78) 0.767 
Hs-CRP 2.6 [1.1 – 7.0] 2.6 [1.0 - 6.5] 1.4 [0.7 - 2.4] 0.142 0.85 (0.48-1.48) 0.558 
F2-isoprostanes 40 [31 - 51] 41 [31 - 57] 41 [30 - 44] 0.479 2.45 (0.56-10.80) 0.235 
F3-isoprostanes 1.0 [0.5 – 4.0] 2.0 [0.5 – 4.0] 0.5 [0.5 – 3.0] 0.125 1.50 (0.75-3.02) 0.251 
Isofurans 36 [23 - 50] 36 [29 - 56] 28 [22 - 43] 0.371 1.30 (0.49-3.42) 0.598 
ur
in
e F2-isoprostanes 1.23 [0.94 - 1.72] 1.08 [0.64 - 1.94] 0.99 [0.55 - 1.52] 0.133 0.32 (0.09-1.17) 0.084 
F3-isoprostanes 0.12 [0.07 - 0.20] 0.12 [0.06 - 0.24] 0.12 [0.07 - 0.16] 0.943 0.95 (0.49-1.86) 0.889 
Isofurans 1.86 [1.31 - 2.31] 1.73 [1.00 - 2.74] 1.46 [1.05 - 1.77] 0.211 0.81 (0.25-2.58) 0.717 
Connexin 43 Normal+normal N=11 
Normal + Abnor 
N=146 
Ab + Abnormal 
N=74 P* 









NT-proBNP 459 [273 - 674] 255 [115 - 791] 308 [174 - 1012] 0.408 1.41 (0.72-2.75) 0.310 
Hs cTnT 7.6 [4.9 - 16.0] 12.7 [7.0 - 21.6] 10.1 [6.4 - 20.7] 0.564 1.11 (0.51-2.45) 0.788 
Hs-CRP 5.2 [0.7 - 5.7] 2.3 [1.1 – 7.0] 2.3 [1.0 - 5.2] 0.720 0.88 (.048-1.64) 0.696 
F2-isoprostanes 39 [35 - 51] 41 [31 - 54] 42 [31 - 52] 0.928 2.34 (0.40-13.86) 0.349 
F3-isoprostanes 3.0 [0.5 – 4.0] 1.0 [0.5 – 4.0] 2.0 [0.5 - 3.3] 0.764 1.61 (0.74-3.48) 0.231 
Isofurans 35 [20 - 55] 37 [25 - 53] 35 [25 - 51] 0.872 1.11 (0.36-3.40) 0.862 
ur
in
e F2-isoprostanes 1.55 [1.21 - 2.02] 1.18 [0.85 - 1.58] 1.11 [0.69 - 1.75] 0.131 0.46 (0.11-1.97) 0.296 
F3-isoprostanes 0.32 [0.16 - 0.34] 0.11 [0.07 - 0.19] 0.12 [0.06 - 0.19] 0.064 0.97 (0.48-1.98) 0.939 
Isofurans 1.83 [1.08 - 2.60] 1.83 [1.31 - 2.29] 1.73 [1.00 - 2.43] 0.615 0.66 (0.16-2.70) 0.566 
*P for Kruskal Wallis test. † Biomarkers were log-transformed and included in logistic regression analysis with the 
histopathological feature dependent adjusted for age, COPD, history of Atrial Fibrillation, heart failure, valve surgery 
and EuroSCORE log. Three classes of Connexin 43: normal pattern (patients with control Cx43 junctional and 
little/absent Cx43 lateralization); normal + abnormal pattern (patients with control Cx43 junctional and present Cx43 
lateralization or patients with depressed Cx43 junctional and little/absent Cx43 lateralization); abnormal pattern 
(patients with depressed Cx43 junctional and present Cx43 lateralization; or patients with heterogeneous Cx43 
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Table 5. Literature analysis of papers focused on Post-Operative Atrial Fibrillation, subdivided 
by methods of histological evaluations. 
 
 Total 
Methods of histological analysis 
Automatic Semi-automatic No Automatic 
Nr of papers, n 19 4 2 13 




















Age overall (years), mean±SD 63±7 62±13 58±12 65±3 
Age of POAF (years), mean±SD 68±7 74±0 61±17 69±4 
Sex (Male), n (%) 1200 (66) 189 (74) 80 (48) 931 (66) 
Type of surgery,  
Coronary bypass, n/n 













Multivariate analysis, n/n 13/19 2/4 2/2 9/13 
Biomarkers, n 12/19 1/12 2/2 9/13 
Histological variables analyzed 
Fibrosis, n/n 15/19 3/4 2/2 10/13 




1/15 not clear 
2/3 Yes 
1/3 No 2/2 Yes 
4/10 Yes 
5/10 No 
1/10 not clear 
Myocytolysis, n/n 8/19 1/4 1/2 6/13 










Hypertrophy of cardiomyocytes, 
n/n 6/19 1/4 0/2 5/13 
Hypertrophy of cardiomyocytes 
association with POAF, n/n 
1/6 Yes 
5/6 No 1/1 No - 
4/5 Yes 
1/5 No 
Cx43, n/n 3/19 2/4 0/2 1/13 
Cx43 association with POAF, n/n 1/3 Yes 2/3 No 
1/2 Yes 




Automatic: the measurements were performed by using a computer image analyzer; semi-automatic: the 
measurements were performed manual and with a computer-assisted image analyzer; No Automatic: the 
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Table 6. Literature analysis of papers focused on Other Types of Atrial Fibrillation, subdivided 




Methods of histological analysis 
Automatic Semi-automatic No Automatic 
Nr of papers, n 30 15 6 9 
Nr of patients (without animals),  

















Age(years) of patients, mean±SD 56±9 53±9 57±10 60±7 
Age of AF (years), mean±SD 61±11 57±8 70±18 62±9 
Sex (Male), n (%) 1061 (57) 486 (58) 229 (62) 346 (51) 
Type of surgery 



















Multivariate analysis, n/n 6/30 3/15 2/6 2/9 
Biomarkers, n 7/30 4/15 2/6 1/9 
Histological variables analyzed 
Fibrosis, n/n 20/30 11/15 3/6 6/9 
Fibrosis association with POAF, n/n 18/20 Yes 
2/20 No 
11/11 Yes 
 3/3 Yes 
4/6 Yes 
2/6 No 
Myocytolysis, n/n 6/30 - 2/6 4/9 
Myocytolysis association with POAF, 
n/n 5/6 Yes 1/6 not 
clear 
- 2/2 Yes  
3/4 Yes 
1/4 not clear 
Hypertrophy of cardiomyocytes, n/n 
5/30 1/15 1/6 3/9 
Hypertrophy of cardiomyocytes 
association with POAF, n/n 
5/5 Yes 
 1/1 Yes 1/1 Yes 3/3 Yes 
Cx43, n/n 1/30 - 1/6 - 
Cx43 association with POAF, n/n 1/1 No - 1/1 No - 
 
Automatic: the measurements were performed by using a computer image analyzer; semi-automatic: the 
measurements were performed manual and with a computer-assisted image analyzer; No Automatic: the 








Figure 1. A. Low-power histopathological view of a RAA biopsy with mild-to-moderate 
hypertrophy of the pectinate muscles (arrow) and moderate subepicardial fibro-adipose 
thickening (arrowhead). B. A detail of the region in A marked by an asterisk, with moderate-to-
severe interstitial fibrosis (arrow). C. Intermediate-power view of a RAA biopsy with moderate 
interstitial fibrosis and cardiomyocytes with transverse diameters within the normal limits. D. C. 
Intermediate-power view of a RAA biopsy with moderate interstitial fibrosis and cardiomyocytes 
with enlarged transverse diameters. Stainings: A-B hematoxylin-eosin; C-D Periodic acid–
Schiff. Original magnifications: A x2 (scale bar: 2mm), B-D x20 (scale bar: 150μm). 
 
Figure 2. RAA biopsies including cardiomyocytes (arrows) A. without glycogen deposition, B. 
with mild glycogen deposition, C. with moderate glycogen deposition, and D. with severe 
glycogen deposition. Staining: A-D Periodic acid–Schiff (PAS). Original magnifications: A-D 
x40 (scale bar: 100μm). 
 
Figure 3. RAA myocardial fibrosis. A. Interstitial fibrosis within the normal limits and sparse 
myocytolytic cardiomyocytes (arrow). B. Mildly increased perivascular fibrosis around deep-
penetrating myocardial blood vessels (arrow). C. Mild-to-moderate myocardial interstitial 
fibrosis (arrow). D. Severe myocardial interstitial fibrosis (arrow). Staining: A-D Van Gieson 






 http://ahajournals.org by on July 12, 2020
24 
Figure 4. Connexin 43 immunosignal. A. Control distribution of Connexin 43 at the intercalated 
disks. B. Depressed signal at the intercalated disks. C. Profound lateralization of Connexin 43. D. 
Near-absence Connexin 43 immunosignal. A-D confocal microscopy. Original magnifications: 
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What is Known: 
• Post-operative atrial fibrillation (POAF) occurs in 30-50% of patients undergoing cardiac 
surgery and is associated with increased morbidity and mortality. 
• The lack of understanding of the specific preceding anatomic and molecular changes in 
the atrial myocardium at the time of cardiac surgery that might influence the risk of 
POAF is a major limitation in developing preventive strategies. 
 
What the Study Adds: 
• In 239 patients undergoing cardiac surgery (35.2% developed POAF), right atrial 
appendage (RAA) was excised, fixed, paraffin embedded and analyzed. 
• On top of well-known risk factors for POAF (i.e. advanced age, heart failure, COPD, 
higher EuroSCORE, valve surgery), none of the histological features (i.e. fibrosis, 
myocytolysis, cardiomyocyte diameter, glycogen score, Connexin 43 distribution) was 
independently associated with risk of POAF. 
• RAA structural remodeling does not reflect changes in other parts of the atria, shown to 
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